DENVER — KromaTiD, Inc. announced it successfully completed its A round of financing with Denver-based firm First Capital Ventures. KromaTiD said its traction and potential within the gene-editing market have enabled the company to close this round at 100%. The amount of the financing was not disclosed.
KromaTiD said the funding will enable the company to advance the development of its directional Genomic Hybridization (dGHTM) platform in order to continue providing gene editing with unique and essential tools for understanding the success and quality of edits at the cellular level. The financing will contribute to dGH platform capability and capacity expansion, including further optimization of critical artificial intelligence-based image analysis capabilities, the company said. These improvements will allow KromaTiD to meet the growing demand from the company’s partners for single cell structural genomic analysis to support their therapeutic development programs.
“We are confident in the unique abilities of our platform to enable gene editing therapies with essential development and quality data, and now we have the financial resources to capitalize on this opportunity,” said Christopher Tompkins, KromaTiD CEO. “Not only did First Capital share our confidence in our platform and the KromaTiD team, they realize the transformative potential of gene editing and, through this funding, are enabling us to play a role in the gene-editing value chain.”